Summary

Overview
Global Locally Advanced Pancreatic Cancer market reached US$ 0.9 billion in 2022 and is expected to reach US$ 2.0 billion by 2030, growing with a CAGR of 11.1% during the forecast period 2023-2030.
Pancreatic cancer is generally represented by its aggressive tumor expansion and dismal prognosis. When patients demonstrate pancreatic cancer, less than 10% have tumors that are potentially treatable with resection, and roughly one-third have metastatic conditions. The rest (more than one-half of all patients with pancreatic cancer) have a condition that is believed to be locally progressive and unresectable pancreatic cancer (LAPC) as an outcome of local invasion of adjacent structures.
Pancreatic adenocarcinoma is among the most aggressive therapy of tumor and is expected to emerge as the second top reason for cancer-related mortalities in Europe and the United States by 2030. The projection has barely enhanced over the last twenty years and stays down, with a general 5-year survival rate of roughly 8% individuals affected with the condition. Pancreatic cancer is generally diagnosed in later stages, and unintended weight loss, continued loss of hunger, etc. are a few manifestations noticed in patients. The treatment for locally advanced pancreatic cancer includes surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy selected depending on the condition.
The growing cases of pancreatic cancer, increasing initiatives to spread awareness, and support efforts among other factors are expected to boost the global locally advanced pancreatic cancer market growth during the forecast period. Further, the increasing research activities owing to the rising fundings and investments are expected to boost the global Locally Advanced Pancreatic Cancer market growth in the forecast period.
Dynamics
Growing Cases of Locally Advanced Pancreatic Cancer Drive the Market Growth
The growing cases of locally advanced pancreatic cancer globally are expected to boost the global market growth during the forecast period. For instance, approximately 30% of individuals with pancreatic cancer are with locally advanced conditions. Also, according to an article published by NCBI, about 21,859 new patients of pancreatic cancer were registered in Germany in 2021. The growth in nicotine smoking and the increase in tobacco consumption are among the factors leading to the boost in the number of patients with this cancer.
Moreover, according to the forecasts made in Advances in Pancreatic Ductal Adenocarcinoma Diagnosis and Treatment article, the number of individuals with pancreatic cancer is expected to grow. By 2025, it is assessed that the number of fresh cases will grow by 9829, and by 2040 by 37,824. The pancreatic cancer-caused mortality is expected to rise to 141,653 deaths in 2025, and to 169,389 in 2040 around 37,255 more deaths compared to 2020. Again, according to WCRF International, pancreatic cancer is the 12th most typical cancer globally. It is the 12th most typical cancer in males and the 11th most expected cancer in females. There were over 495,000 fresh cases of pancreatic cancer in 2020.
Increasing Research Developments
The increasing research development for the treatment for pancreatic cancer treatment are expected to boost the global locally advanced pancreatic cancer market growth in the forecast period. For instance, The January 2022, Multitargeted T-cell therapy was awarded orphan drug status by the U.S. Food and Drug Administration (FDA) for the therapy of pancreatic cancer. When utilized in combination with chemotherapy, this therapy has the prospect of producing long-lasting results in individuals with progressive or metastatic pancreatic cancer.
Further, in January 2022, Novartis AG obtained an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It integrates with additional chemotherapy medicines for the treatment of pancreatic cancer and other tumors. Similarly, in June 2023, RenovoRx, Inc., a clinical-stage biopharmaceutical corporation designing targeted blend therapies, delivered new positive data on progression-free survival (PFS) from the pivotal Phase III open-label TIGeR-PaC investigation of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer (LAPC).
High Therapy Costs
The high cost of pancreatic cancer therapy is estimated to hamper the global locally advanced pancreatic cancer market growth in the forecast period. For instance, according to the American Society of Clinical Oncology, a six-month course of chemotherapy (Gemcitabine) expends about US$ 23,500. With the mixture of the drug Erlotinib, the therapy expenses are around USD 40,000.
Pancreatic cancer therapy is a highly priced therapy, for individuals without health coverage, pancreatic cancer therapy generally costs approximately $50,000-$200,000 or above, based on the kind and span of therapy. Total episode costs for pancreatic cancer care ranged from $35,601 (FOLFOX) to $45,851 (liposomal irinotecan), but the cost elements vary by regimen followed. Similarly, according to NIH, the unadjusted intermediate expense for pancreatic resection and corresponding hospitalization was around $20,352.
Therapy Side-effects
The side effects of chemotherapy rely on which medications are administered. Also, not all individuals have identical side effects even if the same medication is given. Overall the side effects include poor hunger, nauseousness, vomiting, diarrhea, gastrointestinal issues, hives, mouth sores, hair loss, and a deficiency of energy. Individuals accepting chemotherapy are even additional prone to hold low levels of WBCs, RBCs, and Thrombocytes, which puts the individuals at an increased threat of anemia, infections, bruising, and bleeding.
A few drugs utilized in pancreatic cancer are even connected with typical side effects. For instance, capecitabine can provoke redness and discomfort on the palms of the hands and the soles of the feet. This state is called hand-foot syndrome. Oxaliplatin can induce cold sensitivity numbness and tingling in the fingers and toes, anointed peripheral neuropathy. Peripheral neuropathy is an unwanted effect of nab-paclitaxel as well.
Segment Analysis
The global locally advanced pancreatic cancer market is segmented based on therapy, route of administration, end-user and region.
Chemotherapy is Expected to Dominate Market
Chemotherapy is estimated to hold a major share of the global locally advanced pancreatic cancer market which is around 38.6% of the market share as the initial treatment for locally advanced pancreatic cancer is systemic chemotherapy. The introduction of FOLFIRINOX chemotherapy and gemcitabine-nab-paclitaxel (gem-nab) holds significant importance for the management and results of patients with locally advanced pancreatic cancer.
For instance, according to a clinical investigation post 4–6 months of induction chemotherapy, the bulk of individuals showed steady condition or even tumor-regression. Around 12 to 35% of individuals successfully downstaged to resectable condition. Further, according to the first interim analysis of the phase III TIGeR-PaC trial presented at ESMO GI 2023, in individuals with locally advanced pancreatic cancer, therapy with intra-arterial gemcitabine directs to better survival and safety results than with the standard-of-care therapy with intravenous gemcitabine/nab-paclitaxel.
Geographical Penetration
Increasing Number of Pancreas Cancer Cases in North America
North America is estimated to hold around 38.2% of the total market share in 2023. Owing to the increasing number of pancreas cancer cases, government funding, and awareness initiatives are boosting the regional market growth during the forecast period. For instance, the American Cancer Society’s Cancer Facts & Figures 2023, indicates that an assessed over 64,050 Americans to be detected with pancreatic cancer in 2023, more individuals than ever in history. Also, approximately 50,550 Americans are expected to die from the condition in 2023.
Further, pancreatic cancer is presently the 10th most highly detected cancer in the U.S., it remains the third-leading reason for cancer-related deaths. Pancreatic cancer is on the path to evolve as the second-highest reason for cancer-related mortalities before 2030. Similarly, according to the CDC Annual Report to the Nation 2022, in males, the most significant incidence rate boost was witnessed in pancreatic cancer, which grew by 1.1% per year, and the abruptest incidence rate reduction was witnessed in lung cancer, which fell by 2.6% per year. Furthermore, in August 2022, PanTher Therapeutics, a clinical-stage oncology corporation designing next-generation targeted treatments for solid tumors, acquired $14.2 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
The grant is intended to be employed to extend clinical development via Phase 2 of PanTher’s principal investigational treatment, PTM-101, a minimally invasive, implantable therapy for non-metastatic pancreatic cancer that delivers a direct, sustained discharge of a known therapeutic drug at the tumor location. Additionally, in June 2023, a $3.3 million grant from the National Cancer Institute by the U.S. Department of Health and Human Services was awarded to UTHealth Houston to investigate a combination strategy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with chemotherapy for pancreatic cancer.
Russia-Ukraine War Impact
The Russia-Ukraine conflict has negatively impacted the global locally advanced pancreatic cancer market growth. Since the invasion of Ukraine in February 2022, the execution of clinical trials has become quite difficult owing to the deterioration of healthcare establishments and patient displacement. For instance, according to an illustrative investigation, and narrative examination was conducted utilizing data from cancer clinical trials with sites in Russia or Ukraine employing the ‘clinical trials.gov’ online database between February 2022 and May 2022.
There were 508 clinical trials concerning locations in Ukraine or Russia. A majority of these were global investigations accounting for 93% of total studies. The most of investigations were phase 3 accounting for 68% of the total and these even held the most extensive specimen sizes ranging from 12–5637. This has created disruption in the treatment research activities hampering the growth in the forthcoming years.
COVID-19 Impact Analysis
The pandemic had an intermediate impact on the global market as at the beginning many procedures and visits were postponed or canceled which negatively impacted the market. However, according to the Pancreatic Cancer Organization UK, several individuals with pancreatic cancer are at elevated threat of becoming extremely ill if exposed to coronavirus infection. Individuals with people with cancer who are having chemotherapy have compromised immunity since the chemotherapy weakens the immune system, making it harder for the body to resist an infection.
Also, individuals who have had their spleen extracted, as some surgery for pancreatic cancer concerns removing the spleen are at increased threat for infection since the spleen is an important part of the immune system. Similarly, the individuals undergoing radiotherapy or immunotherapy may also be at elevated risk. This has caused immediate actions to restore the pancreatic cancer healthcare assistance programs.
By Therapy
• Chemotherapy
o Gemcitabine
o 5-fluorouracil (5-FU)
o Oxaliplatin
o Albumin-bound paclitaxel (Abraxane)
o Capecitabine (an oral 5-FU drug)
o Cisplatin
o Irinotecan
o Others
• Immunotherapy
o Dostarlimab
o Pembrolizumab
• Targeted Therapy
o Larotrectinib
o Entrectinib
• Radiation Therapy
• Surgery
o Whipple Procedure
o Total Pancreatectomy
o Distal Pancreatectomy
By Route of Administration
• Oral
• Injectables
• Others
By End-User
• Hospital
• Specialty Clinics
• Research Institutions
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In January 2022, Novartis AG obtained an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It integrates with other chemotherapy medications for the treatment of pancreatic cancer and other tumors.
• In January 2022, AstraZeneca teamed with Scorpion Therapeutics to discover, design, and market precision therapies against formerly hard-to-target cancer proteins.
• In September 2021 F. Hoffmann-La Roche Ltd collaborated with NovoCure to design Tumor Treating Fields (TTFields) in a mixture with anti-PD-L1 therapy, atezolizumab, for individuals detected with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Competitive Landscape
The major global players in the market include Theratechnologies Inc., Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, AbbVie, Galderma Laboratories, L.P. and GlaxoSmithKline among others.
Why Purchase the Report?
• To visualize the global locally advanced pancreatic cancer market segmentation based on therapy, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of locally advanced pancreatic cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.
The global locally advanced pancreatic cancer market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals

ページTOPに戻る

Table of Contents